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During Wave IV, Add Health collected biological specimens from a large, nationally 
representative sample of young adults.  Given the size of the Wave IV sample, its geographic 
distribution, and in-home setting of the respondent interviews, biological specimen collection 
involved practical, relatively non-invasive, cost-efficient and innovative methods.  These 
methods included collection of capillary whole blood via finger prick by trained and certified 
field interviewers, its in situ desiccation, then shipment, assay and archival of dried blood spots.  
The collection of capillary whole blood followed the collection of cardiovascular and 
anthropometric measures (Entzel et al. 2009) and saliva (Smolen et al. 2013).  It preceded the 
collection of data on respondent use of prescription and select over-the-counter medications 
(Tabor et al. 2010).  Further details on the design of Add Health Waves I-IV, are available 
elsewhere (Harris 2012; Harris et al. in press). 
 
Included in the Add Health Wave IV restricted use and public use data are thirteen constructed 
measures designed to facilitate analysis and interpretation of lipids results: 
 Total cholesterol decile 
 High-density lipoprotein cholesterol decile 
 Triglycerides decile 
 Total cholesterol measurement method 
 High-density lipoprotein cholesterol measurement method 
 Triglycerides measurement method 
 Low-density lipoprotein cholesterol decile 
 Non-high-density lipoprotein cholesterol decile 
 Total to high-density lipoprotein cholesterol ratio decile 
 Fasting duration 
 Fasted for nine hours or more 
 Antihyperlipidemic medication use 
 Hyperlipidemia 
 
This document summarizes the rationale, equipment, protocol, assay, internal quality control, 
data cleaning, external quality control, and classification procedures for each measure listed 
above.  Measures of glucose homeostasis, inflammation, immune function, and candidate genes 
are documented elsewhere (Whitsel et al. 2012a, 2012b; Smolen et al. 2013).   
 
2. General Overview of Data Collection  
 
A Blaise computer-assisted interview (CAI) program guided trained and certified field 
interviewers (FIs) through the blood spot collection process.  Help screens with step-by-step 




Booklet that served as a quick reference guide to study protocols. 
 
Respondents were free to decline any or all measurements and specimen collections while 
participating in other components of the interview.  In the Wave IV data set, any measures that 
are missing due to unique interview circumstances at correctional facilities are coded as 
legitimate skips.   
 
Some measurement protocols were revised in the period between the Wave IV Pretest 
(conducted in 2007) and the Main Study (conducted in 2008).  Where the Pretest and Main Study 
data collection protocols differed significantly, this report documents the key differences 
between them.  Pretest cases in the Wave IV data set are flagged for identification.   
 




Capillary whole blood was collected to provide Add Health with the biological specimens 
necessary to assay and interpret a pre-specified panel of metabolic, hematologic, inflammatory, 
and immune biomarkers, including the lipid panel described below.  It also was collected to 
establish a dried capillary whole blood spot archive capable of supporting future assays and 
ancillary studies.  
 




















Equipment included sterile lancets, a rubber strap, alcohol prep pads, gauze, Band-Aid type 
adhesive dressings, gloves, a biohazard container, a Chux-type absorbent underpad, and a seven-
spot capillary whole blood collection card (Whatman 903® Protein Saver, Whatman Inc., 





3.3.1 Main Study 
 
During the preceding anthropometric data collection procedure, all female respondents were 
asked specifically whether they had a prior mastectomy and, if so, on which side.  If there were 
contraindications to using the right hand for capillary whole blood collection, the left hand was 
used.  If there were contraindications on both hands, capillary whole blood was not collected.       
 
FIs collected capillary whole blood from the respondent’s middle or ring finger, unless one of the 
following contraindications was present:   
 
 open sores, wounds, gauze dressings or rashes; 
 casts, splints or shunts; 
 intravenous (IV) catheters or other attached medical devices; 
 swelling, withering or paralysis; or 
 finger on same side as prior mastectomy.   
 
FIs prepared the work surface for capillary whole blood collection and donned gloves. The help 
screen on the computer laptop directed FIs to refer to the Job Aids Booklet for the Fainting 
Protocol.  FIs selected a finger for the procedure, cleaned it with the alcohol prep pad, and let it 
fully dry.  While the finger was drying, FIs asked respondents to hang the selected finger below 
their waist while applying the rubber strap to the midpoint of the upper, ipsilateral arm.  After 
placing the rubber strap, FIs started a timer on the laptop computer designed to sound an audible 
cue after three minutes to prompt removal of the rubber strap.  FIs placed the clean finger against 
the work surface and firmly placed a sterile lancet against it to prick the fingertip, slightly lateral 
of center. FIs firmly wiped away the first drop of capillary whole blood with gauze, applying 
pressure to the base of (but not milking) the finger to facilitate flow. FIs were trained to allow a 
large droplet to accumulate before dropping it onto the first circle of the seven-spot capillary 
whole blood collection card and to do the same for the remaining six circles from left to right, all 




Exhibit 2. Collecting the capillary whole blood. 
 
 
When seven capillary whole blood spots were successfully collected (or blood droplet formation 
ceased), FIs wiped off remaining blood with gauze, instructed respondents to firmly apply the 
gauze to the finger for at least two minutes, and then applied an adhesive dressing to it.  FIs 
collecting fewer than five spots less than 80% full from a single prick requested respondents’ 
permission to repeat the capillary whole blood collection procedure on a second finger from the 
contralateral hand.  FIs asked respondents to discard used capillary whole blood collection 
equipment in their own trash receptacle (except for lancets which were discarded in the 
biohazard container).  FIs discarded them in the biohazard container when interviews were 
conducted in public locations. 
 
FIs bar code labeled each capillary whole blood spot collection card with the corresponding 
respondent biospecimen ID and then air dried it for three hours.  Thereafter, FIs packaged each 
card with a desiccant pack and shipped it in a FedEx Priority Overnight envelope to the 
University of Washington Department of Laboratory Medicine (UW Lab Med, Mark H. Wener, 
M.D., Director, Seattle, WA) for assay. 
 
UW Lab Med received the FedEx Priority Overnight envelopes containing a single dried blood 
spot collection card and desiccant pack.  They scanned the FedEx tracking number and bar code-
labeled card into a database in the order of receipt. They also keyed the receipt date, number of 
dried blood spots per card (0-7), number of adequate blood spots per card defined by blood 
filling ≥ 80% of the target area (0-7), comments on dried blood spot quality, and condition of the 
desiccant pack alongside the biospecimen ID.  They grouped the cards (≤ 25 per group), sealed 
the groups in Ziploc bags with desiccant packs, and stored them at -70°C until processing.  
Immediately before processing, they warmed cards to room temperature (23°C) and re-scanned 
the bar code-labeled card into the database.  The cards were punched for all assays except 
hemoglobin A1c (HbA1c), returned to the freezers, then shipped frozen to the Carolina Population 
Center (CPC, University of North Carolina, Chapel Hill, NC) for permanent archival.  At the 
CPC, Spot #1 on each card was removed, re-bundled (≤ 25 per group), sealed in plastic bags with 
desiccant, and shipped frozen by next day air to FlexSite Diagnostics, Inc. (Robert A. Ray, 
Ph.D., Director, Palm City, FL) for HbA1c assay (see Whitsel et al. 2012a  for documentation of 





3.3.2 Pretest Methodological Variations 
 
During the Pretest, respondents chose the middle or ring finger and FIs were directed not to use 
the thumb, index finger or fifth digit/little finger for capillary whole blood collection.  FIs also 
collected up to ten capillary whole blood spots:  three on a BIOSAFE Blood Collection Card for 
HbA1c and Cholesterol Panel (BIOSAFE Laboratories, Inc., Chicago, IL) and seven more on a 
Whatman 903® Protein Saver, (Whatman Inc., Piscataway, NJ).  The BIOSAFE card was made 
of Whatman 903® filter paper (Whatman International, Dassel, Germany) with a top layer of 
TELFA (Kendall Healthcare Products, Mansfield, MA) to minimize the effects of blood spot 
layering and inadvertent touching of cards with respondent fingertips (Bui et al. 2002a, 2002b; 
Grzeda et al. 2002; Maggiore, 2002; Tyrrell, 1999).  A stabilizing borate buffered preservative 
was pre-applied by BIOSAFE to the area of the BIOSAFE card designated for HbA1c assay and 
dried.  As in the main study, the Whatman 903® Protein Saver card was shipped to UW Lab 
Med for the Pretest and Main Study lipid assays. 
 
4. Measures of Lipids 
 
4.1 Lipid Panel 
 
4.1.1 Rationale  
 
Cholesterol and triglyceride are lipids that travel through the blood in protein-containing 
particles called lipoproteins.  The particles include low-density lipoprotein cholesterol (LDL-C), 
high-density lipoprotein cholesterol (HDL-C), and other relatively triglyceride (TG)-rich 
lipoproteins.  Their concentrations are associated with cardiovascular disease risk (Cui et al. 
2001; Klag et al. 1993; Srinivasan et al. 2006; Stamler et al. 2000) and are targets of 
antihyperlipidemic therapy (National Cholesterol Education Panel 2002).  Total cholesterol (TC), 
HDL-C, and TG were therefore assayed in dried capillary whole blood spots. 
4.1.2 Assays and Internal Quality Control 
 
4.1.2.1 Colorimetric Assays 
 
As described below, the three lipids were initially assayed using colorimetric procedures that 
measure change in color (optical density) reflective of increases in plasma lipid concentrations. 
 
4.1.2.1.1 Total Cholesterol 
 
The dried blood spot (DBS) total cholesterol colorimetric assay involves a series of coupled 
enzymatic reactions. A punch from a DBS card containing a total cholesterol (TC) assay 
calibrator, quality control (QC) sample or respondent sample is eluted with a buffer solution. The 
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elution solution is incubated with assay reagent containing cholesterol ester hydrolase, 
cholesterol oxidase, peroxidase, and a chromogen. The cholesterol ester hydrolase catalyzes the 
conversion of cholesterol esters to cholesterol, and this and de novo cholesterol is oxidized by 
cholesterol oxidase, producing hydrogen peroxide (H2O2) as a byproduct. In the presence of 
peroxidase, the H2O2 reacts with the chromogen causing the solution to develop color. The TC 
concentration is directly proportional to the absorbance of the solution; absorbance is measured 
spectrophotometrically. A standard curve is constructed by plotting the absorbance values of the 
calibrators against the known TC concentrations. Using the standard curve, the absorbance 
values of the QC samples and patient samples are read as TC concentrations. Acceptability of the 
assay is determined by comparing the TC concentrations of the QC samples with their 
established values. 
 
DBS TC assay calibrators were constructed from high TC concentration pooled human plasma 
(University of Washington Department of Laboratory Medicine, Seattle, WA; UW Lab Med) 
serially diluted with 7% bovine serum albumin in phosphate buffered saline (BSA/PBS; Sigma 
Aldrich, St. Louis, MO) to the desired final TC concentration. Two DBS QC samples were 
constructed from a separate pool of human plasma, either undiluted (high TC concentration QC 
sample) or diluted with BSA/PBS (low TC concentration QC sample). Each calibrator and QC 
sample solution was mixed with a constant volume of washed human erythrocytes (UW Lab 
Med), pipetted in 75µl aliquots onto No. 903 filter paper (Whatman, Piscataway, NJ) and dried 
for 4hr at room temperature (23°c). The final TC concentration of each calibrator and QC sample 
solution was determined by analysis on a UniCel DxC 800 Synchron Clinical System (Beckman 
Coulter, Miami, FL). DBS calibrators, QC samples and study samples were sealed in Ziploc bags 
with desiccant packs and stored at -70°c until processing. Immediately prior to processing, DBS 
were warmed to room temperature and then a single 3.2mm (1/8in) diameter punch was punched 
from each DBS card into a microtiter plate well (Greiner Bio-One, Monroe, North Carolina). 
Microtiter plates were either immediately assayed or were firmly sealed and stored at -70°c 
pending assay. 
 
Immediately prior to assay, microtiter plates were warmed to room temperature. 75µl 
Cholesterol Assay Elution Buffer (Synermed, Westfield, IN) was added to each microtiter plate 
well. The plate was sealed and gently shaken overnight on a microplate shaker (Delfia 
Plateshake, PerkinElmer, Waltham, MA). 275µl Cholesterol Assay Reagent (Synermed) was 
added to each well, the plate gently shaken for 30sec and then incubated for 30min at 37°. 20µl 
Cholesterol Assay Precipitation Buffer (Synermed) was added to each well, the plate gently 
shaken for 30sec and then centrifuged for 10min at 2300rpm to pellet particulates. 200µl of the 
solution was removed from each well without disturbing the pellet and transferred to an assay 
microtiter plate. The plate was gently shaken for 30sec and the absorbance (optical density) of 
each well was read at 630nm by a microtiter plate reader (Synergy HT, BioTek, Winooski, VT). 
A linear regression calibration curve, constructed by plotting the assigned concentrations of the 
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calibrators against the recorded absorbance values, was used to convert the OD value of each 
sample into a DBS TC concentration (Gen5 Software, BioTek). 
 
The TC assay lower limit of detection was 21mg/dl, within-assay imprecision (CV) was 10.9% 
and between-assay imprecision was 14.4%. The correlation between the TC concentrations of 
112 DBS samples analyzed by the DBS assay and the TC concentrations of paired plasma 
samples was improved by adjusting the DBS TC value by the DBS sample hemoglobin 
absorbance per the empiric formula DBS TC value X (1 + [sample hemoglobin absorbance - 
mean sample hemoglobin absorbance]). The linear relationship (Pearson R = 0.93) was Plasma 
TC value = (hemoglobin absorbance-adjusted DBS TC value – 36.051) / 1.472. 
 
4.1.2.1.2 High-Density Lipoprotein Cholesterol 
 
The dried blood spot (DBS) HDL cholesterol colorimetric assay involves a series of coupled 
enzymatic reactions. A punch from a DBS card containing a HDL cholesterol (HDL-C) assay 
calibrator, quality control (QC) sample or respondent sample is eluted with a buffer solution. The 
elution solution is mixed with a reagent containing a chromogen and anti-human β-lipoprotein 
antibody to bind non-HDL lipoproteins into nonreactive complexes. A second reagent, 
containing cholesterol ester hydrolase, cholesterol oxidase and peroxidase, is then added. The 
cholesterol ester hydrolase catalyzes the conversion of HDL-C into cholesterol, which is in turn 
oxidized by cholesterol oxidase and produces hydrogen peroxide (H2O2) as a byproduct. In the 
presence of peroxidase, H2O2 reacts with the chromogen causing the solution to develop color. 
The HDL-C concentration is directly proportional to the absorbance of the solution; absorbance 
is measured spectrophotometrically. A standard curve is constructed by plotting the absorbance 
values of the calibrators against the known HDL-C concentrations. Using the standard curve, the 
absorbance values of the QC samples and patient samples are read as HDL-C concentrations. 
Acceptability of the assay is determined by comparing the HDL-C concentrations of the QC 
samples with their established values. 
 
DBS HDL-C assay calibrators were constructed from high HDL-C concentration pooled human 
plasma (University of Washington Department of Laboratory Medicine, Seattle, WA; UW Lab 
Med) serially diluted with 7% bovine serum albumin in phosphate buffered saline (BSA/PBS; 
Sigma Aldrich, St. Louis, MO) to the desired final HDL-C concentration. Two DBS QC samples 
were constructed from a separate pool of human plasma, either undiluted (high HDL-C 
concentration QC sample) or diluted with BSA/PBS (low HDL-C concentration QC sample). 
Each calibrator and QC sample solution was mixed with a constant volume of washed human 
erythrocytes (UW Lab Med), pipetted in 75µl aliquots onto No. 903 filter paper (Whatman, 
Piscataway, NJ) and dried for 4hr at room temperature (23°c). The final HDL-C concentration of 
each calibrator and QC sample solution was determined by analysis on a UniCel DxC 800 
Synchron Clinical System (Beckman Coulter, Miami, FL). DBS calibrators, QC samples and 
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study samples were sealed in Ziploc bags with desiccant packs and stored at -70°c until 
processing. Immediately prior to processing, DBS were warmed to room temperature and then 
three 3.2mm (1/8in) diameter punches were punched from each DBS card into a microtiter plate 
well (Greiner Bio-One, Monroe, North Carolina). Microtiter plates were either immediately 
assayed or were firmly sealed and stored at -70°c pending assay. 
 
Immediately prior to assay, microtiter plates were warmed to room temperature. 75µl 
Cholesterol Assay Elution Buffer (Synermed, Westfield, IN) was added to each microtiter plate 
well. The plate was sealed and gently shaken overnight on a microplate shaker (Delfia 
Plateshake, PerkinElmer, Waltham, MA). 200μl of EZ HDL Cholesterol Reagent 1 (Trinity 
Biotech, St Louis, MO) was added, the plate gently shaken for 30sec and then incubated at 37°c 
for 45min. At the conclusion of this incubation, 60μl of EZ HDL Cholesterol Reagent 2 (Trinity 
Biotech) was added, the assay plate shaken for 30sec and then incubated at 37°c for 30min. 17µl 
HDL Cholesterol Precipitation Buffer was added to each well, the plate gently shaken for 30sec 
and then centrifuged for 10min at 2300rpm to pellet particulates. 200µl of the solution was 
removed from each well without disturbing the pellet and transferred to an assay microtiter plate. 
The plate was gently shaken for 30sec and the absorbance (optical density) of each well was read 
at 590nm by a microtiter plate reader (Synergy HT, BioTek, Winooski, VT). A linear regression 
calibration curve, constructed by plotting the assigned concentrations of the calibrators against 
the recorded absorbance values, was used to convert the OD value of each sample into a DBS 
HDL-C concentration (Gen5 Software, BioTek). 
 
The HDL-C assay lower limit of detection was 9mg/dl, within-assay imprecision (CV) was 5.8% 
and between-assay imprecision was 5.9%. The correlation between the HDL-C concentrations of 
112 DBS samples analyzed by the DBS assay and the HDL-C concentrations of paired plasma 
samples was improved by adjusting the DBS HDL-C value by the DBS sample hemoglobin 
absorbance per the empiric formula DBS HDL-C value X (sample hemoglobin absorbance / 
mean sample hemoglobin absorbance). The linear relationship (Pearson R = 0.91) was Plasma 




The dried blood spot (DBS) triglycerides colorimetric assay involves a series of coupled 
enzymatic reactions. Punches from a DBS card containing a triglycerides (TG) assay calibrator, 
quality control (QC) sample or respondent sample are eluted with a buffer solution. TG in the 
elution solution is hydrolyzed by lipase to produce glycerol, the glycerol is phosphorylated by 
glycerol kinase to produce glycerol-3-phosphate which, in turn, is oxidized by glycerophosphate 
oxidase producing hydrogen peroxide (H2O2) as a byproduct. In the presence of peroxidase, the 
H2O2 reacts with a chromogen causing the solution to develop color. The TG concentration is 
directly proportional to the absorbance of the solution, measured by spectrophotometry. A 
standard curve is constructed by plotting the absorbance values of the calibrators against their 
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known TG concentrations. Using the standard curve, the absorbance values of the QC samples 
and patient samples are read as TG concentrations. Acceptability of the assay is determined by 
comparing the TG concentrations of the QC samples with their established values. 
 
DBS TG assay calibrators were constructed from high TG concentration pooled human plasma 
(University of Washington Department of Laboratory Medicine, Seattle, WA; UW Lab Med) 
serially diluted with 7% bovine serum albumin in phosphate buffered saline (BSA/PBS; Sigma 
Aldrich, St. Louis, MO) to the desired final TG concentration. Two DBS QC samples were 
constructed from a separate pool of human plasma, either undiluted (high TG concentration QC 
sample) or diluted with BSA/PBS (low TG concentration QC sample). The final TG 
concentration of each calibrator and QC sample solution was determined by analysis on a UniCel 
DxC 800 Synchron Clinical System (Beckman Coulter, Miami, FL). Each calibrator and QC 
sample solution was mixed with a constant volume of washed human erythrocytes (UW Lab 
Med), pipetted in 75µl aliquots onto No. 903 filter paper (Whatman, Piscataway, NJ) and dried 
for 4hr at room temperature (23°c). DBS calibrators, QC samples and study samples were sealed 
in Ziploc bags with desiccant packs and stored at -70°c until processing. Immediately prior to 
processing, DBS cards were warmed to room temperature and then two 3.2mm (1/8in) diameter 
punches were punched from each DBS card into a microtiter plate well (Greiner Bio-One, 
Monroe, North Carolina). Microtiter plates were either immediately assayed or were firmly 
sealed and stored at -70°c pending assay. 
 
Immediately prior to assay, microtiter plates were warmed to room temperature. 75µl of 100% 
methanol (Sigma Aldrich, St. Louis, MO) was added to each microtiter plate well. The plate was 
sealed and gently shaken for 3hr at room temperature on a microplate shaker (Delfia Plateshake, 
PerkinElmer, Waltham, MA). 275µL Triglycerides Assay Reagent (Beckman Coulter, Brea, CA) 
was added to each well, the plate gently shaken for 30sec and then incubated for 30min at 37°. 
200 µl of the reaction mixture was transferred from each well of the elution plate to a second 
microtiter plate. The plate was gently shaken for 30sec and the absorbance (optical density) of 
each well was read at 515nm by a microtiter plate reader (Synergy HT, BioTek, Winooski, VT). 
A linear regression calibration curve, constructed by plotting the assigned concentrations of the 
calibrators against the recorded absorbance values, was used to convert the OD value of each 
sample into a DBS TG concentration (Gen5 Software, BioTek). 
 
The TG assay lower limit of detection was less than 20mg/dl, within-assay imprecision (CV) was 
7.1% and between-assay imprecision was 8.9%. The TG concentrations of 112 DBS samples 
analyzed by the DBS assay correlated with the TG concentrations of paired plasma samples 
analyzed by the DxC 800 (Pearson R = 0.97) and were linearly related (Plasma TG = [DBS TG 





4.1.2.2 Fluorimetric Assays 
 
During the course of field work, colorimetric methods were replaced with fluorimetric 
alternatives, described below.  The anticipated advantages of the fluorimetric methods—which 
involve ultraviolet excitation of and spectroscopic measurement of light emitted from 
fluorochromes—led to their adoption.  Overall, 13905, 13676, and 13596 respondents had either 
a colorimetric or fluorimetric concentration of TC, HDL-C, and TG, respectively.  Of these 
respondents, 95%, 82% and 63% had a colorimetric concentration, while 46%, 47%, and 47% 
had a fluorimetric concentration of the respective measures.  Inter-conversion of colorimetric and 
fluorimetric concentrations is described below (Section 4.1.2.4). 
 
4.1.2.2.1 Total Cholesterol 
 
The dried blood spot (DBS) total cholesterol fluorimetric assay involves a series of coupled 
enzymatic reactions. A punch from a DBS card containing a total cholesterol (TC) assay 
calibrator, quality control (QC) sample or respondent sample is eluted with a buffer solution. The 
elution solution is incubated with assay reagent containing cholesterol ester hydrolase, 
cholesterol oxidase, peroxidase, and a fluorogen. The cholesterol ester hydrolase catalyzes the 
conversion of cholesterol esters to cholesterol, and this and de novo cholesterol is oxidized by 
cholesterol oxidase, producing hydrogen peroxide (H2O2) as a byproduct. In the presence of 
peroxidase, the H2O2 reacts with the non-fluorescent fluorogen to produce a fluorescent 
fluorophore. The TC concentration is directly proportional to the fluorescent intensity of the 
solution; fluorescence is measured spectrophotometrically. A standard curve is constructed by 
plotting the fluorescence values of the calibrators against the known TC concentrations. Using 
the standard curve, the fluorescence values of the QC samples and patient samples are read as 
TC concentrations. Acceptability of the assay is determined by comparing the TC concentrations 
of the QC samples with their established values. 
 
DBS TC assay calibrators were constructed from high TC concentration pooled human plasma 
(University of Washington Department of Laboratory Medicine, Seattle, WA; UW Lab Med) 
serially diluted with 7% bovine serum albumin in phosphate buffered saline (BSA/PBS; Sigma 
Aldrich, St. Louis, MO) to the desired final TC concentration. Two DBS QC samples were 
constructed from a separate pool of human plasma, either undiluted (high TC concentration QC 
sample) or diluted with BSA/PBS (low TC concentration QC sample). Each calibrator and QC 
sample solution was mixed with a constant volume of washed human erythrocytes (UW Lab 
Med), pipetted in 75µl aliquots onto No. 903 filter paper (Whatman, Piscataway, NJ) and dried 
for 4hr at room temperature (23°c). The final TC concentration of each calibrator and QC sample 
solution was determined by analysis on a UniCel DxC 800 Synchron Clinical System (Beckman 
Coulter, Miami, FL). DBS calibrators, QC samples and study samples were sealed in Ziploc bags 
with desiccant packs and stored at -70°c until processing. Immediately prior to processing, DBS 
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were warmed to room temperature and then a single 3.2mm (1/8in) diameter punch was punched 
from each DBS card into a microtiter plate well (Greiner Bio-One, Monroe, North Carolina). 
Microtiter plates were either immediately assayed or were firmly sealed and stored at -70°c 
pending assay. 
 
Immediately prior to assay, microtiter plates were warmed to room temperature. A TC elution 
buffer comprised of 400µl ddH2O with 0.1% Triton X-100 (Sigma) was added to each microtiter 
plate well. The plate was sealed and gently shaken for 1hr on a microplate shaker (Delfia 
Plateshake, PerkinElmer, Waltham, MA). 20μl of eluent was transferred from each well of the 
elution plate to an assay microtiter plate. This was followed by addition of 100μl of TC assay 
reagent comprised of 70% Cholesterol Chromogen (Synermed, Westfield, IN), 29% Cholesterol 
Enzyme (Synermed) and 1% Cayman ADHP (10-acetyl-3,7-dihydroxyphenoxazine; Cayman 
Chemical, Ann Arbor, MI). The plate was gently shaken for 30sec and then incubated at 37°c for 
30min. The fluorescence intensity (RFU) of each well was read at 530/25nm excitation and 
590/35nm emission by a microtiter plate reader (Synergy HT, BioTek, Winooski, VT). A linear 
regression calibration curve, constructed by plotting the assigned concentrations of the 
calibrators against the recorded fluorescence values, was used to convert the RFU value of each 
sample into a DBS TC concentration (Gen5 Software, BioTek). 
 
The TC assay lower limit of detection was 27mg/dl, within-assay imprecision (CV) was 4.0% 
and between-assay imprecision was 4.7%. The TC concentrations of 105 DBS samples analyzed 
by the DBS assay correlated with the TC concentrations of paired plasma samples (Pearson R = 
0.93) and were linearly related (Plasma TC = [DBS TC – 17.141] / 1.582). Correction for 
hematocrit did not improve the agreement between the serum and DBS TC values. 
 
4.1.2.2.2 High-Density Lipoprotein Cholesterol 
 
The dried blood spot (DBS) HDL cholesterol fluorimetric assay involves a series of coupled 
enzymatic reactions. A punch from a DBS card containing an HDL cholesterol (HDL-C) assay 
calibrator, quality control (QC) sample or respondent sample is eluted with deionized water. The 
elution solution is mixed with a reagent containing anti-human β-lipoprotein antibody (to bind 
non-HDL lipoproteins into nonreactive complexes) and a flurogen. A second reagent, containing 
cholesterol ester hydrolase, cholesterol oxidase and peroxidase, is then added. The cholesterol 
ester hydrolase catalyzes the conversion of HDL-C into cholesterol, which is in turn oxidized by 
cholesterol oxidase and produces hydrogen peroxide (H2O2) as a byproduct. In the presence of 
peroxidase, H2O2 reacts with the non-fluorescent fluorogen to produce a fluorescent fluorophore. 
The HDL-C concentration is directly proportional to the fluorescent intensity of the solution; 
fluorescence is measured spectrophotometrically. A standard curve is constructed by plotting the 
fluorescence values of the calibrators against the known HDL-C concentrations. Using the 
standard curve, the fluorescence values of the QC samples and patient samples are read as HDL-
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C concentrations. Acceptability of the assay is determined by comparing the HDL-C 
concentrations of the QC samples with their established values. 
 
DBS HDL-C assay calibrators were constructed from high HDL-C concentration pooled human 
plasma (University of Washington Department of Laboratory Medicine, Seattle, WA; UW Lab 
Med) serially diluted with 7% bovine serum albumin in phosphate buffered saline (BSA/PBS; 
Sigma Aldrich, St. Louis, MO) to the desired final HDL-C concentration. Two DBS QC samples 
were constructed from a separate pool of human plasma, either undiluted (high HDL-C 
concentration QC sample) or diluted with BSA/PBS (low HDL-C concentration QC sample). 
Each calibrator and QC sample solution was mixed with a constant volume of washed human 
erythrocytes (UW Lab Med), pipetted in 75µl aliquots onto No. 903 filter paper (Whatman, 
Piscataway, NJ) and dried for 4hr at room temperature (23°c). The final HDL-C concentration of 
each calibrator and QC sample solution was determined by analysis on a UniCel DxC 800 
Synchron Clinical System (Beckman Coulter, Miami, FL). DBS calibrators, QC samples and 
study samples were sealed in Ziploc bags with desiccant packs and stored at -70°c until 
processing. Immediately prior to processing, DBS were warmed to room temperature and then a 
single 3.2mm (1/8in) diameter punch was punched from each DBS card into a microtiter plate 
well (Greiner Bio-One, Monroe, North Carolina). Microtiter plates were either immediately 
assayed or were firmly sealed and stored at -70°c pending assay. 
 
Immediately prior to assay, microtiter plates were warmed to room temperature. 400µl diH2O 
HDL-C elution buffer was added to each microtiter plate well. The plate was sealed and gently 
shaken for 1hr on a microplate shaker (Delfia Plateshake, PerkinElmer, Waltham, MA). 40μl of 
eluent was transferred from each well of the elution plate to an assay microtiter plate. This was 
followed by addition of 75μl of HDL-C assay reagent 1 comprised of 99% EZ HDL Cholesterol 
Reagent 1 (Trinity Biotech, St Louis, MO) and 1% Cayman ADHP (10-acetyl-3,7-
dihydroxyphenoxazine; Cayman Chemical, Ann Arbor, MI). The plate was gently shaken for 
30sec and then incubated at 37°c for 25min. At the conclusion of this incubation, 25μl of HDL-C 
assay reagent 2 (EZ HDL Cholesterol Reagent 2; Trinity Biotech) was added, the assay plate 
shaken for 30sec and then incubated at 37°c for 30min. The fluorescence intensity (RFU) of each 
well was read at 530/25nm excitation and 590/35nm emission by a Synergy HT Microtiter Plate 
Reader (BioTek, Winooski, VT). A linear regression calibration curve, constructed by plotting 
the assigned concentrations of the calibrators against the recorded fluorescence values, was used 
to convert the RFU value of each sample into a DBS HDL-C concentration (Gen5 Software, 
BioTek). 
 
The HDL-C assay lower limit of detection was 15mg/dl, within-assay imprecision (CV) was 
5.3% and between-assay imprecision was 9.9%. The HDL-C concentrations of 104 DBS samples 
analyzed by the DBS assay correlated with the HDL-C concentrations of paired plasma samples 
(Pearson R = 0.88) and were linearly related (Plasma HDL-C = [DBS HDL-C – 32.941] / 0.965). 
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The dried blood spot (DBS) triglycerides (TG) fluorimetric assay involves a series of coupled 
enzymatic reactions. A punch from a DBS card containing a TG assay calibrator, quality control 
(QC) sample or respondent sample is eluted with a buffer solution. TG in the elution solution is 
hydrolyzed by lipase to produce glycerol, the glycerol is phosphorylated by glycerol kinase to 
produce glycerol-3-phosphate which, in turn, is oxidized by glycerophosphate oxidase producing 
hydrogen peroxide (H2O2) as a byproduct. In the presence of peroxidase, the H2O2 reacts with a 
non-fluorescent fluorogen, converting it into a fluorescent fluorophore. The TG concentration is 
directly proportional to the fluorescence intensity of the solution, measured by 
spectrophotometry. A standard curve is constructed by plotting the fluorescence values of the 
calibrators against the known TG concentrations. Using the standard curve, the fluorescence 
values of the QC samples and patient samples are read as TG concentrations. Acceptability of the 
assay is determined by comparing the TG concentrations of the QC samples with their 
established values. 
 
DBS TG assay calibrators were constructed from high TG concentration pooled human plasma 
(University of Washington Department of Laboratory Medicine, Seattle, WA; UW Lab Med) 
serially diluted with 7% bovine serum albumin in phosphate buffered saline (BSA/PBS; Sigma 
Aldrich, St. Louis, MO) to the desired final TG concentration. Two DBS QC samples were 
constructed from a separate pool of human plasma, either undiluted (high TG concentration QC 
sample) or diluted with BSA/PBS (low TG concentration QC sample). Each calibrator and QC 
sample solution was mixed with a constant volume of washed human erythrocytes (UW Lab 
Med), pipetted in 75µl aliquots onto No. 903 filter paper (Whatman, Piscataway, NJ) and dried 
for 4hr at room temperature (23°c). The final TG concentration of each solution used to create a 
DBS calibrator or QC sample was determined by analysis on a UniCel DxC 800 Synchron 
Clinical System (Beckman Coulter, Miami, FL). DBS calibrators, QC samples and study samples 
(created from approximately five single 50µl drops of whole blood obtained from a finger-stick 
placed separately on Protein Saver Card No. 903 filter paper (Whatman) and dried at room 
temperature) were sealed in Ziploc bags with desiccant packs and stored at -70°c (Thermo 
Scientific Revco Ultima Plus, Fisher Scientific, Pittsburg, PA) until processing. Immediately 
prior to processing, DBS were warmed to room temperature and then a single 3.2mm (1/8in) 
diameter punch was punched from each DBS card using a BSD700 Semi-Automated Dried 
Sample Puncher (BSD Robotics, Brisbane, QLD, Australia) into a deep-well microtiter plate 
well (Greiner Bio-One, Monroe, NC). Microtiter plates were either immediately assayed or were 




Immediately prior to assay, microtiter plates were warmed to room temperature. A TG elution 
buffer comprised of 400µl ddH2O with 0.1% Triton X-100 (Sigma) was added to each microtiter 
plate well. The plate was sealed and vigorously shaken for 1hr on a microplate shaker (Delfia 
Plateshake, PerkinElmer, Waltham, MA). 40 µl of eluent was transferred from each well of the 
elution plate to a shallow-well assay microtiter plate (Greiner Bio-One). This was followed by 
addition of 100μl of eluent was transferred from each well of the elutiChromogen Reagent 
(Beckman, Brea, CA), 5% Triglycerides Enzyme Reagent (Beckman) and 1% Cayman ADHP 
(10-acetyl-3,7-dihydroxyphenoxazine; Cayman Chemical, Ann Arbor, MI). The plate was gently 
shaken for 30sec and then incubated at 37°c for 30min (Lindberg/Blue M, Asheville, NC). The 
fluorescence intensity (RFU) of each well was read at 530/25nm excitation and 590/35nm 
emission by a microtiter plate reader (Synergy HT, BioTek, Winooski, VT). A linear regression 
calibration curve, constructed by plotting the assigned concentrations of the calibrators against 
the recorded fluorescence values, was used to convert the RFU value of each sample into a DBS 
TG concentration (Gen5 Software, BioTek). An assay would be rejected if the mean value of a 
control sample was greater than 3SD above or below the established mean value, or if the mean 
value of each control sample was greater than 2SD above or below the respective established 
mean value. 
 
The TG assay lower limit of detection was 20mg/dl, within-assay imprecision was 7.6%CV and 
between-assay imprecision was 9.4%CV. The TG concentrations of 106 DBS samples analyzed 
by the DBS assay correlated with the TG concentrations of paired plasma samples (Pearson R = 
0.98) and were linearly related (Plasma TG = [DBS TG + 10.3] / 1.438). 
 
4.1.2.3 Data Cleaning 
 
Plate-specific, linear regression calibration formulae were used to verify laboratory conversion of 
optical density to lipid concentrations (mg/dl). Seasonal variation was examined by plotting 
dried blood spot and quality control lipid concentrations (mg/dl) versus receipt date (2007-2009) 
on a single calendar time scale (1-366 days). Relatively conspicuous patterns of seasonal 
variation were observed in colorimetric and fluorimetric TC and HDL-C concentrations (e.g. 
Exhibit 3). They were therefore modeled as a function of time, represented by four seasonal 
terms: sine(2Πjt÷366) and cosine(2Πjt÷366), where harmonic j = (1, 2) and time t = (1, 2, 3, …, 
366). These non-linear models were adjusted for age (yr), sex (male; female), and race/ethnicity 
(non-Hispanic white; non-Hispanic black; non-Hispanic Asian/Pacific Islander; Mexican; other 
Hispanic/Latino; other race/multiracial). Goodness of fit as measured by the Akaike information 
criterion was greatest for these models when compared to a variety of non-linear and linear 
alternatives. The age-, sex- and race/ethnicity-adjusted harmonic terms estimated in the former 
model were subtracted from the assayed concentrations of TC and HDL-C (mg/dl). Subtraction 
had little effect on the overall distribution, mean, or variance of TC and HDL-C, but attenuated 

















4.1.2.4 Inter-Conversion of Colorimetric and Fluorimetric Assay Results 
 
Four respondents were randomly selected from each of 24 Add Health Wave IV Main Study 
strata defined by race / ethnicity (non-Hispanic white; non-Hispanic black; Hispanic; other), sex 
(male; female) and TG tertile (low, medium, high). Collectively, the stratified, random sample 
included 4 × 24 = 96 respondents whose dried capillary whole blood spot collection cards were 
submitted for colorimetric and fluorimetric assays by laboratory staff masked to respondent 
identity. The associations between paired colorimetric and fluorimetric concentrations were 
modeled using Deming regression (Cornbleet et al. 1979; Deal et al. 2011), i.e. colorimetric 
concentration = α + β × fluorimetric concentration. Compared to estimates of α (95% confidence 
interval), β (95% confidence interval), and the Pearson correlation coefficient in the stratified 
random sample, estimates in much larger convenience samples of overlapping concentrations 
were comparable, but more precise:  0.66 (0.25, 1.08), 0.95 (0.86, 1.04) and 0.47 for log TC in 
5,805 respondents; -24.12 (-31.10, -17.15), 1.34 (1.27, 1.40) and 0.92 for TG in 1,288 
respondents; and 17.05 (15.25, 18.85), 0.91 (0.85, 0.97), and 0.55 for HDL-C in 4,040 
respondents (Exhibit 4). In the event of missing colorimetric, but non-missing fluorimetric 
results, the latter values of α and β were therefore used to convert fluorimetric to colorimetric 
concentrations (See Section 6.2 Flags). 
 
Exhibit 4. Plots of colorimetric versus fluorimetric TC, HDL-C and TG concentrations 
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Capillary whole blood was collected twice, one to two weeks apart, from a race / ethnicity- and 
sex-stratified random sample of 100 Add Health respondents, 14% and 17% of whom were 
fasting ≥ 9 hr at visits 1 and 2.  The reliabilities of TC, HDL-C and TG concentrations in this 
sample were estimated as intra-class correlation coefficients (95% confidence intervals):  0.40 
(0.22-0.58), 0.39 (0.21-0.57) and 0.71 (0.60-0.81), respectively.  Assuming 95% confidence and 
a 5% type II error rate, corresponding values of the minimal detectable difference in TC, HDL-C 





Three plasma pools, together representing low, medium, and high concentrations of TC, HDL-C 
and TG were obtained from the Lipid Standardization Program, Centers for Disease Control and 
Prevention (CDC, Atlanta, GA) and mixed with washed erythrocytes.  The plasma-erythrocyte 
mixture from each pool was used to spot twenty capillary whole blood collection cards.  One 
card per pool was submitted to the laboratory twice per week over a ten-week period for assay of 
TC, HDL-C and TG by laboratory staff masked to origin of the cards.  Mean laboratory – CDC 
differences in TC, HDL-C and TG concentrations were large:  -6, 15, and 30 mg/dl.  However, 
corresponding Pearson correlation coefficients were high:  0.66, 0.73, and 0.85.  Moreover, in 
the Add Health population as a whole, expected among-group differences were observed in 
HDL-C (male << female), TG (fasting << non-fasting), and in TC and TG (normal << 
hyperlipidemic respondents) (Table 1). 
 
 
Table 1. Percent* of respondents in the highest lipid decile, by select attributes 
  Sex Fasting ≥ 9 hr Hyperlipidemia
† 
Lipid Male Female Yes No Yes No 
TC 10.7 10.1 9.0 10.7 15.6 9.9 
HDL-C 6.7 13.5 8.4 10.4 11.0 10.0 
TG 14.0 6.6 5.9 11.0 22.2 9.1 





6. Constructed Measures 
 
6.1  Lipid Deciles 
 
Variables: TC, HDL and TG 
After de-trending, and when necessary, inter-converting assay results, total cholesterol (TC), 
high-density lipoprotein cholesterol (HDL), and triglyceride (TG) concentrations (mg/dl) were 
ordered and assigned decile ranks which are reported here. Absolute concentrations (in mg/dl) 
will remain unavailable given their distinctive reliance on dried capillary whole blood, nascent 
assay technologies, de-trending, inter-conversion of fluorimetric to colorimetric concentrations, 




Variables: TC_FLG, HDL_FLG and TG_FLG 
Flags were constructed to identify the method of measuring total cholesterol (TC_FLG), high-
density lipoprotein cholesterol (HDL_FLG), and triglycerides (TG_FLG).  Flags took the value 
“Assayed” (2) when colorimetrically assayed; “Imputed” (1) when converted from fluorimetric 
assay results; “Missing” (.) when blood spots were unavailable, and “No result” (9) when assay 
failed. 
 
6.3 Low-Density Lipoprotein Cholesterol Decile 
 
Variable: LDL 
When the triglyceride concentration was < 400 mg/dL, a low-density lipoprotein cholesterol 
concentration (mg/dl) was indirectly calculated from the concentrations (mg/dl) of total 
cholesterol, high-density lipoprotein cholesterol and triglycerides, as follows:  LDL-C = TC – 
HDL-C – [TG  5] (Friedewald et al. 1972).  Concentrations were then ordered and assigned 
decile ranks.    
 
6.4 Non-High-Density Lipoprotein Cholesterol Decile 
 
Variable: NON_HDL 
Although use of the Friedewald equation (Friedewald et al. 1972) is routine, interpretation of 
indirectly calculated LDL-C is difficult in the presence of post-prandial hypertriglyceridemia.  
The non-high-density lipoprotein cholesterol concentration (mg/dl) was therefore calculated 
from the concentrations (mg/dl) of total cholesterol and high-density lipoprotein cholesterol, as 
follows:  non-HDL-C = TC – HDL-C.  This difference—which is reliable in the non-fasting state 




6.5 Total to High-Density Lipoprotein Cholesterol Ratio Decile 
 
Variable: TC_HDL 
Although the ratio of total to high-density lipoprotein cholesterol concentrations (mg/dl) is 
neither a primary nor secondary target of antihyperlipidemic therapy (National Cholesterol 
Education Panel, 2002), the ratio has been described as a simple and powerful predictor of 
cardiovascular disease risk (Castelli et al. 1992; Criqui and Golomb 1998; Hong et al. 1991; 
Kinosian et al. 1995).  It was therefore calculated, as follows:  TC:HDL-C = TC / HDL-C, then 
ordered and assigned decile ranks. 
 
6.6 Fasting Duration (hr) 
 
Variable: FASTTIME 
In Interview Section 4: General Health and Diet, field interviewers asked respondents the 
following question: “At what time did you last eat or drink anything other than water, including 
sugar-containing candy or gum?” The response to the question was recorded in hours and 
minutes and designated AM or PM. On-screen instructions of  “12 MIDNIGHT IS AM. 12 
NOON IS PM” were provided to the field interviewer for clarification. To calculate fasting 
times, responses to the above question were subtracted from the laptop time stamp at the start of 
the interview. Since laptop clocks were set to Eastern Time for field work processing, the CPC 
Spatial Analysis Unit corrected interview start times using geocoded respondent locations, the 
time zones in which they were located, and the U.S. Daylight Savings Time schedule. In a final 
step, fasting times also were adjusted for interviews that stopped prematurely, but resumed later. 
Data on fasting times (range: 0-23.9 hr) were missing for 141 respondents, the result of recoding 
implausible values (> 24 hr), missing time zone data, breakoff interviews that resumed before 24 
hours elapsed such that the question was not repeated, unrealistic computer timestamps, and 
answers of “don’t know” or “refused” to the question. 
 
6.7 Fasted for Nine Hours or More 
 
Variable: FAST_LIP 
Respondents who were fasting (≥ 9 hr) and non-fasting (< 9 hr) at the time of blood collection 
were identified (1,0) based on recommendations of the Expert Panel on Detection, Evaluation, 






6.8 Antihyperlipidemic Medication Use 
 
Variable: C_MED2 
Use of antihyperlipidemic medications as captured by the Wave IV medication inventory (Tabor 
et al, 2010) may confound lipid-based estimates of cardiovascular disease risk. Respondents 
using an antihyperlipidemic medications in the past four weeks with one of the following 
therapeutic classification codes were therefore assigned a value of 1: 
 
358-019-173 HMG-CoA reductase inhibitors 
358-019-174 Miscellaneous antihyperlipidemic agents  
358-019-241 Fibric acid derivatives  
358-019-252 Bile acid sequestrants  
358-019-316 Cholesterol absorption inhibitors  
358-019-317 Antihyperlipidemic combinations 
 
Respondents not using an anithyperlipidemic were assigned a value of 0. The (1,0) classification 
should be used cautiously in the investigation or control of potential confounding because 
selection biases often threaten the study of non-randomized medication exposures. 
 
6.9 Joint Classification of Self-Reported History of Hyperlipidemia and Antihyperlipidemic 
Medication Use 
 
Variable:  C_JOINT2 
Respondents were jointly classified as having hyperlipidemia if they had self-reported history of 
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